MedPath

ZAFEMY

These highlights do not include all the information needed to use ZAFEMY safely and effectively. See full prescribing information for . Initial U.S. Approval: 2001

Approved
Approval ID

77230a20-4269-4abf-ae2a-ac5ccafef565

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 5, 2024

Manufacturers
FDA

Bryant Ranch Prepack

DUNS: 171714327

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Norelgestromin and Ethinyl Estradiol

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code72162-2220
Application NumberANDA213950
Product Classification
M
Marketing Category
C73584
G
Generic Name
Norelgestromin and Ethinyl Estradiol
Product Specifications
Route of AdministrationTRANSDERMAL
Effective DateJanuary 5, 2024
FDA Product Classification

INGREDIENTS (6)

NORELGESTROMINActive
Quantity: 150 ug in 1 d
Code: R0TAY3X631
Classification: ACTIB
CROSPOVIDONEInactive
Code: 2S7830E561
Classification: IACT
DIPROPYLENE GLYCOLInactive
Code: E107L85C40
Classification: IACT
ETHINYL ESTRADIOLActive
Quantity: 35 ug in 1 d
Code: 423D2T571U
Classification: ACTIB
POLYBUTENE (1400 MW)Inactive
Code: 1NA5AO9GH7
Classification: IACT
OLEYL ALCOHOLInactive
Code: 172F2WN8DV
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ZAFEMY - FDA Drug Approval Details